Skip to content
Head to head

Mineralys Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MLYS · VRTX

Updated 5 minutes ago

1-year performance, rebased to 100

MLYS -69.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
MLYSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.66515.02
Change today-3.53%-1.08%
1-year return-67.4%+22.0%
Market cap$1.21B$130.58B
52-week range13.57 – 44.13412.27 – 568.67
Valuation
P/E (TTM)-3.1833.14
P/E percentile, own 5-yr range94th99th
P/B2.406.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.2915.32
Net profit (TTM)$-202.80M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-153.03M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership115.9%96.8%
Insider activity (12mo)7 buy / 43 sell28 buy / 22 sell
Short interest (% of float)8.7%1.9%
Analyst consensus83% buy / 17% hold (6)95% buy / 5% hold (21)
Analyst price target$46 (+233%)$624 (+21%)
StockVane view
StockVane Quant RatingE (2)C (68)
Company
Employees766,400
Founded20191989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.